celastrol has been researched along with Experimental Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, HG; Gautam, M; Jin, SG; Kim, JO; Ku, SK; Nguyen, HT; Oh, KT; Ou, W; Soe, ZC; Thapa, RK; Yong, CS | 1 |
| Huang, J; Huang, Q; Lu, W; Pan, J; Tang, K; Wu, G; Zeng, J | 1 |
| Choi, HG; Choi, JY; Jeong, JH; Kim, J; Kim, JO; Kim, JR; Kim, SY; Ku, SK; Ramasamy, T; Yong, CS; Youn, YS | 1 |
| Jin, Y; Lai, Y; Lu, Z; Pan, J; Qiu, L | 1 |
| Li, J; Li, Y; Li, Z; Liang, D; Lin, J; Shi, Y; Sun, L; Wu, X; Yao, L; Zhang, W | 1 |
| Hong, YS; Jin, HZ; Jung, HS; Koo, TH; Lee, JH; Lee, JJ; Lee, K; Yoon, H | 1 |
6 other study(ies) available for celastrol and Experimental Neoplasms
| Article | Year |
|---|---|
Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pentacyclic Triterpenes; Structure-Activity Relationship; Triterpenes; Tumor Cells, Cultured | 2018 |
Design, synthesis and biological evaluation of C6-modified celastrol derivatives as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Hep G2 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pentacyclic Triterpenes; Triterpenes; Xenograft Model Antitumor Assays | 2014 |
PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Topics: Animals; Axitinib; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Imidazoles; Indazoles; Lipid Bilayers; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Pentacyclic Triterpenes; Porosity; Silicon Dioxide; Triterpenes | 2016 |
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; Pentacyclic Triterpenes; Piperazines; Pyrimidines; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2010 |
Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drugs, Chinese Herbal; Humans; Hydrogen-Ion Concentration; Lactones; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasms, Experimental; Pentacyclic Triterpenes; Polyethylene Glycols; Retinoblastoma; Triterpenes; Xenograft Model Antitumor Assays | 2012 |
Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; DNA-Binding Proteins; Female; Gene Expression; Genes, Reporter; HeLa Cells; Humans; I-kappa B Kinase; Inflammation; Jurkat Cells; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; Pentacyclic Triterpenes; Phosphorylation; Triterpenes | 2006 |